Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported net product revenue of $26.2 million for the first quarter of 2026, a significant increase from $9.0 million in the same period last year. The company achieved a positive gross margin for the first time, driven by strong launches of AUCATZYL in the US and UK. Autolus is implementing a cost reduction initiative, including a 13% workforce reduction, which is expected to reduce operating expenses by $15 million annually starting in 2027.
Key figures
- Revenue
- 26218000
- Guidance
- AUCATZYL net product revenue of $120 million to $135 million for full year 2026, up from $74 million in 2025
- Revenue Yoy
- 191.9%
- Net loss
- 71598000
- Gross profit
- 1600000
- Sga expenses
- 39953000
- Total assets
- 527065000
- Cost of sales
- 24568000
- R and d expenses
- 21210000
- Total liabilities
- 418239000
- Loss from operations
- 59513000
- Total current assets
- 368835000
- Marketable securities
- 98509000
- Cash and cash equivalents
- 130925000
- Total current liabilities
- 63599000
- Total shareholders equity
- 108826000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.